nature portfolio

Dr Tisné Carine
NCOMMS-23-5798

Corresponding author(s):

Last updated by author(s): Feb 19, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				•
<u> </u>	トつ	1	ıct	100
.)	ıa	ш	เรา	ics

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on statistics for bialogists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

CryoEM Datasets were collected on a 300 kV Titan Krios equipped with a Gatan K3 detector.

Data analysis

Particles were picked and pre-processed with WARP. After migration of particle stacks to cryoSPARC, 2D classification, ab initio reconstruction and 3D non-uniform refinement yielded the final reconstructions. The dataset of Complex 1 was processed in Relion 3.1. Models were docked to the density in Chimera-1.11.2 or ChimeraX V1.5, and some parts were modelled manually in Coot-0-8-9-152 from the CCP4 suite of programs. After model building, structures were subjected to geometrical optimisation with ISOLDE and cycles of real-space refinement in Phenix against the locally filtered cryo-EM maps and manual fitting in Coot.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Policy information about studies involving human research participants and Sex and Gender in Research.

Coordinates and maps have been deposited in the PDB and EMDB databases, respectively: PDB 8CBO and EMD-16547 for Complex 1, PDB 8CBL and EMD-16544 for Complex 2, PDB ID 8CBK and EMD-16543 for Complex 3, PDB 8CBM and EMD-16545 for Complex 4.

Human research participants

Reporting on sex and gender	n.a
Population characteristics	n.a
Recruitment	n.a
Ethics oversight	n.a

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below	that is the best fit for your research.	If you are not sure, read the appropriate sections before making your selection.	
∑ Life sciences	Behavioural & social sciences	Ecological, evolutionary & environmental sciences	
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			

Life sciences study design

Randomization

Blinding

n.a

n.a

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

	-	
	מנטת	ر
	\subset	3
	=	₹
	a	
	$\frac{C}{C}$	۲.
	≻	ζ.
	C	
		7
	=	Į
	5	
	\succeq	<u>_</u>
	7	
	C)
÷		
	÷	
	<u>۔</u>	3
	<u>ر</u>	5
	<u>a</u>	5
	<u>ر</u>	5
	<u>ر</u>	
		507
		2007
	Ξ	で で で に に に に に に に に に に に に に
. (Ξ	2004
	Ξ	201
	Ξ	
	Ξ	
	Ξ	
	Ξ	
	Ξ	rooting class
	Ξ	
	Ξ	

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a Involved in the study		
\boxtimes	Antibodies	ChIP-seq		
\boxtimes	Eukaryotic cell lines	Flow cytometry		
\boxtimes	Palaeontology and archaeology	MRI-based neuroimaging		
\boxtimes	Animals and other organisms	'		
\boxtimes	Clinical data			
\boxtimes	Dual use research of concern			